Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Januar 2024 - 2:00PM
Immunovant, Inc. (Nasdaq: IMVT),
a clinical-stage immunology company dedicated to enabling normal
lives for people with autoimmune diseases, today announced that
Pete Salzmann, M.D., chief executive officer, will provide a
corporate overview at the 42nd Annual J.P. Morgan Healthcare
Conference on Tuesday, January 9, 2024, at 10:30 am ET.
The presentation will be webcast live and can be
accessed at https://www.immunovant.com/investors/news-events. An
archived webcast will be available for a limited time on
Immunovant’s website.
About Immunovant, Inc.Immunovant,
Inc. is a clinical-stage immunology company dedicated to enabling
normal lives for people with autoimmune diseases. As a trailblazer
in anti-FcRn technology, the Company is developing innovative,
targeted therapies to meet the complex and variable needs of people
with autoimmune diseases. For additional information on the
Company, please visit www.immunovant.com.
Contact:Chau Cheng, PhD, MBAVice
President, Investor RelationsImmunovant,
Inc.info@immunovant.com
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024